Marker Therapeutics, Inc. (MRKR) company profile
Close on Nov 17, 2026Market cap $13.95MP/E –Yield –
About Marker Therapeutics
Pharmaceutical Preparations, SIC 2834
Marker is a clinical-stage immuno-oncology company developing novel T cell-based immunotherapies for hematological cancers and solid tumors. The company focuses on its Multi-Antigen Recognizing T cell platform, which expands natural, non-genetically modified tumor-specific T cells from blood to target multiple antigens simultaneously. Its pipeline features lead autologous candidate MT-601, evaluated for relapsed lymphoma and pancreatic cancer, and off-the-shelf candidate MT-401-OTS for acute myeloid leukemia and myelodysplastic syndromes. Marker serves patients with advanced cancer indications, particularly those with relapsed disease or limited alternatives.
Marker conducts clinical trials across multiple medical centers, including data gathered from seven sites across the United States for its lead lymphoma trial. The company collaborates with Baylor College of Medicine and third-party contract development and manufacturing organizations to support clinical manufacturing and scaling. Marker maintains its operational activities in the United States, though its text does not explicitly identify a specific headquarters city.
Summary of the business section of Marker Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Marker Therapeutics, Inc.
- Headquarters
- Houston, TX
- Address
- 2450 Holcombe Blvd, Tmc Partners Office 1.311 77021
- Phone
- (713) 400-6400
- Website
- markertherapeutics.com
- Employees
- 5, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, Houston, TX
Stock & identifiers
- Ticker
- MRKR
- Former tickers
- TPIV until Nov 13, 2018
- Exchange
- Nasdaq
- IPO date
- Jul 16, 2002
- Shares outstanding
- 17M, Aug 7, 2026
- Public float
- $17.31M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Jan 27, 2023; 1-for-12 reverse, Sep 16, 2016; 1-for-100 reverse, Feb 25, 2014; 1-for-10 reverse, Jul 27, 2009; 1-for-2.5 reverse, Jun 28, 2007
- SEC CIK
- 1094038
- CUSIP
- 57055L206
- ISIN
- US57055L2060
- FIGI
- BBG000GMZP09
- Share class FIGI
- BBG001SKLLN7
- LEI
- 549300ZJ2JUDG0FI5Y49
- EIN
- 88-0277072
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Juan Vera | Chief Executive Officer, Director | 2,671,845 |
| Norman David Eansor | Director | 9,570 |
| Steve Elms | Director | 328,338 |
| Katharine Knobil | Director | 1,500 |
| Kathryn Penkus Corzo | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $415.39K | $641.45K | – | $48 | – |
| FY2024 | $400.00K | $96.78K | – | $57 | – |
| FY2023 Juan Vera | $585.68K | $1.14M | $220.10K | $207 | – |
| FY2023 Peter Hoang | $581.90K | $505.41K | $220.10K | $207 | – |
| FY2022 | $566.17K | $278.14K | $613.01K | $28 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Total | vs. prior year |
|---|---|---|---|---|
| Juan Vera President and Chief Executive Officer | $415.39K | $266.00K | $741.19K | +85% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 5 full-time employees: 1 clinical and 4 in administrative support.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?